Mohamed Wa'el Ahmed Hashad - Jan 1, 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Rachelle Jacques, as Attorney-in-Fact for Mohamed Wa'el Hashad
Stock symbol
AKTX
Transactions as of
Jan 1, 2024
Transactions value $
$0
Form type
3
Date filed
1/2/2024, 07:49 PM
Previous filing
Sep 13, 2023
Next filing
Jan 25, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 5M $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2024 Annual General Meeting.

Remarks:

See Exhibit 24.1 - Power of Attorney